Cargando…
Ph阳性急性淋巴细胞白血病细胞株Sup-B15与基质细胞共培养后对伊马替尼敏感性的变化
OBJECTIVE: To investigate the sensitivity of imatinib (IM) on Sup-B15 Ph(+) acute lmphoblastic leukemia (ALL) cells indused by stromal cells OP9, and to further explore its mechanism. METHODS: The study is divided into two group, Sup -B15 cells group and co-cultured with OP9 cells group (Sup-B15/OP9...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343075/ https://www.ncbi.nlm.nih.gov/pubmed/26134008 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.06.003 |
Sumario: | OBJECTIVE: To investigate the sensitivity of imatinib (IM) on Sup-B15 Ph(+) acute lmphoblastic leukemia (ALL) cells indused by stromal cells OP9, and to further explore its mechanism. METHODS: The study is divided into two group, Sup -B15 cells group and co-cultured with OP9 cells group (Sup-B15/OP9 group). The inhibitory effects of IM on leukemia cells were measured by CCK-8 test, and the apoptosis by Annexin V/7-AAD dyeing and the percentage of CD 34(+) CD38(−)leukemia cells were determined by flow cytometry. ALDH1, CD144, and β-catenin mRNA were detected by real-time RT-PCR, protein levels by Western blot. Inmunoprecipitation was used to detect the level of β-catenin connected to CD144. RESULTS: IM presented inhibitory effects on Sup-B15 and Sup-B15/OP9 cells at multiple concentrations from 10 µmol/L to 45 µmol/L. The IC(50) of IM on Sup-B15/OP and Sup-B15 cells were 35.8 µmol/L and 6.3 µmol/L, respectively (P<0.05). After 24 h of 30 µmol/L IM treatment, the percentages of apoptosis cells in Sup-B15/OP9 and Sup-B 15 cell were (14.24±2.11)% and (3.45±0.68)%, respectively (P<0.05). The percentage of CD34(+)CD38(−)cells in Sup-B15/OP9 group was significantly higher than that in Sup-B15 group [(3.42±0.28)% vs (0.16±0.15)%, P<0.05]. As compared to Sup-B15 cells, the transcription of ALDH1 in Sup-B15/OP9 group was remarkably upregulated (0.097±0.012 vs 0.046±0.010, P<0.05), and the CD133 protein level was also upregulated in Sup-B15/OP9 group. The transcription of CD144 in Sup-B15/OP9 group was remarkably upregulated compared with Sup-B15 group (0.103±0.015 vs 0.010±0.003, P<0.05), as well as the CD144 protein. β-catenin mRNA transcription has no obvious changes between Sup-B15 group and Sup-B15/OP9 group (P>0.05), while the whole β-catenin protein and the cell nucleus β-catenin significantly increased, as well as the β-catenin protein combined with CD144. CONCLUSION: Co-cultured with OP9 cells, Sup-B15 cells show less sensitivity to imatinib. The raising activity of CD144 and CD144/β-catenin signaling may work in this procession. |
---|